Teva Pharmaceutical Industries Ltd ADR Stock
There is an upward development for Teva Pharmaceutical Industries Ltd ADR compared to yesterday, with an increase of €0.50 (1.910%).
With 22 Buy predictions and not a single Sell prediction Teva Pharmaceutical Industries Ltd ADR is an absolute favorite of our community.
With a target price of 31 € there is a slightly positive potential of 16.1% for Teva Pharmaceutical Industries Ltd ADR compared to the current price of 26.7 €.
Our community identified positive and negative aspects for Teva Pharmaceutical Industries Ltd ADR stock for the coming years. 3 users see the criterium "Worthwhile Investment for the next years" as a plus for the Teva Pharmaceutical Industries Ltd ADR stock. On the other hand our users think that "Conscious of the environment" could be a problem in the future.
Pros and Cons of Teva Pharmaceutical Industries Ltd ADR in the next few years
Pros
?
C******** o* t** e**********
?
S********** s********
?
M***** P*******
Cons
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Teva Pharmaceutical Industries Ltd ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Teva Pharmaceutical Industries Ltd ADR | 1.910% | -5.072% | 2.745% | 100.000% | -2.602% | 249.333% | 209.327% |
| Bayer AG ADR | -3.570% | -2.000% | 4.813% | 75.000% | 11.364% | -34.228% | -27.407% |
| Roche Holding AG ADR | -0.600% | 1.831% | 4.545% | 27.422% | 1.134% | 21.992% | 26.422% |
| Novartis AG ADR | -0.800% | -3.846% | -4.215% | 26.518% | 5.485% | 31.857% | 71.233% |
Comments
Teva Pharmaceutical Industries (TEVA) had its price target raised by Bank of America Corporation from $38.00 to $42.00. They now have a "buy" rating on the stock.
Show more
Ratings data for TEVA provided by MarketBeat
Teva Pharmaceutical Industries (TEVA) had its "overweight" rating reaffirmed by Piper Sandler. They now have a $41.00 price target on the stock, up from $40.00.
Show more
Ratings data for TEVA provided by MarketBeat
Teva Pharmaceutical Industries (NYSE:TEVA) had its price target raised by analysts at Truist Financial Corporation from $38.00 to $42.00. They now have a "buy" rating on the stock.
Show more
Ratings data for TEVA provided by MarketBeat